Lilly Pulls Plug on All Tabalumab RA Trials, Citing Lack of Efficacy

Drug Industry Daily
A A
Eli Lilly is pulling the plug on all its tabalumab studies in rheumatoid arthritis (RA) after another Phase III trial found the drug is ineffective.

To View This Article:

Login

Subscribe To Drug Industry Daily